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Abstract
 
It has been recently demonstrated that regulatory CD4
 
 
 
CD25
 
 
 
 CD45RO
 
 
 
 T cells are present
in the peripheral blood of healthy adults and exert regulatory function similar to their rodent
counterparts. It remains difficult to understand how the small fraction of these T cells that reg-
ulate via direct cell-to-cell contact and not via secretion of immunosuppressive cytokines could
mediate strong immune suppression. Here we show that human CD4
 
 
 
CD25
 
 
 
 T cells induce
long-lasting anergy and production of interleukin (IL)-10 in CD4
 
 
 
CD25
 
  
 
T cells. These aner-
gized CD4
 
 
 
CD25
 
  
 
T cells then suppress proliferation of syngenic CD4
 
 
 
 T cells via IL-10 but
independent of direct cell contact, similar to the so-called type 1 regulatory T (Tr1) cells. This
‘catalytic’ function of CD4
 
 
 
CD25
 
 
 
 T cells to induce Tr1-like cells helps to explain their cen-
tral role for the maintenance of immune homeostasis.
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Introduction
 
There is now compelling evidence that CD4
 
 
 
 T cells spe-
cialized for the suppression of immune responses play a
critical role in immune regulation. It has been convincingly
demonstrated in rodents, that cells with this function are
enriched within the CD4
 
 
 
CD25
 
 
 
 subset (1–3). Recent
studies demonstrate that CD4
 
 
 
CD25
 
 
 
 T cells are also rele-
vant as an immune regulator in humans (4–7). It was
shown that CD4
 
 
 
CD25
 
 
 
 T cells similar to their rodent
counterpart constitute a small fraction of CD4
 
 
 
 T cells (av-
erage 6%). They are naturally anergic to mitogenic stimuli,
inhibit the proliferation of CD4
 
 
 
 and CD8
 
 
 
 T cells after
stimulation via their TCR, and do so in a cytokine-inde-
pendent yet cell contact-dependent manner (4–7).
Progress has been made to elucidate the mechanisms by
which CD4
 
 
 
CD25
 
 
 
 T cells exert their regulatory func-
tion. It has been suggested that CD4
 
 
 
CD25
 
 
 
 T cells bind
TGF-
 
 
 
 on their cell surface and thereby mediate contact-
dependent suppression of other T cells (8). Two groups
have described the increased expression of glucocorticoid-
induced TNF receptor (GITR) on CD4
 
 
 
CD25
 
 
 
 T cells
compared with resting CD4
 
 
 
CD25
 
  
 
T cells and they
show, that anti-GITR Abs abrogate CD4
 
 
 
CD25
 
 
 
-medi-
ated suppression (9, 10).
Very little is still known about requirements for the de-
velopment and physiological regulation of CD4
 
 
 
CD25
 
 
 
 T
cell function. Survival and/or expansion of CD4
 
 
 
CD25
 
 
 
T cells in the periphery seems to be dependent on IL-2 and
costimulatory molecules, as mice lacking these components
show major deficiencies in CD4
 
 
 
CD25
 
 
 
 T cells (11–13).
It is difficult to understand how CD4
 
 
 
CD25
 
 
 
 T cells exert
their suppressive function in vivo as they constitute only
6% of CD4
 
 
 
 T cells and need direct cell contact and activa-
tion via their TCR to suppress other T cells. In in vitro ex-
periments usually rather high ratios of CD4
 
 
 
CD25
 
 
 
 T cells
have to be employed to potently suppress proliferation of
CD4
 
 
 
CD25
 
  
 
T cells. These are conditions that probably
would not occur in vivo as CD4
 
 
 
CD25
 
 
 
 T cells, even if
antigen-specifically activated do not expand and proliferate
well because of their anergic state.
It has been shown before that anergized T cells can me-
diate regulatory function on other T cells (14). In this re-
port we show that CD4
 
 
 
CD25
 
 
 
 T cells do not only aner-
gize other CD4
 
 
 
 T cells but that they also induce high
level production of IL-10 in the cells they suppress. The
resulting IL-10–producing anergized T cells are then able
to suppress T cell proliferation in an IL-10–dependent
fashion. These findings give insight into the mechanisms
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used by CD4
 
 
 
CD25
 
 
 
 T cells to execute their important in
vivo function.
 
Materials and Methods
 
Culture Medium.
 
RPMI 1640 (Bio Whitaker) supplemented
with 1% heat-inactivated autologous plasma, 20 
 
 
 
g/ml gentami-
cin (Merck), and 2 mM glutamine (Bio Whitaker) was used for
the generation of dendritic cells (DCs), X-VIVO-20 (Bio Whi-
taker) supplemented with 1% heat-inactivated single donor hu-
man serum, 20 
 
 
 
g/ml gentamicin (Merck), and 2 mM glutamine
(Bio Whitaker) for T cell culture.
 
Cytokines.
 
All cytokines used in this study were recombinant
human proteins. Final concentrations were: 1,000 U/ml GM-
CSF (Leukomax™; Novartis); 800 U/ml IL-4 (Sandoz); and IL-2
(Proleukin; Chiron Corp.) were used at the concentrations indi-
cated; for DC maturation we used a cocktail consisting of 2 ng/
ml IL-1
 
 
 
 (Sigma-Aldrich), 1,000 U/ml IL-6 (Sandoz), 10 ng/ml
TNF-
 
 
 
 (Bender), and 1
 
  
 
g/ml PGE
 
2
 
 (Sigma-Aldrich).
 
Abs.
 
For immunostaining PE- and FITC-conjugated Abs (all
from BD PharMingen) against CD3 (UCHT 1), CD4 (RPA-
T4), CD5 (UCHT 2), CD8 (RPA-T8), CD14 (M5E2), CD19
(HIB 19), CD25 (M-A251), CD28 (CD28.2), CD45 RA (HI
100), CD45 RO (UCHL 1), CD56 (B159), CD62L (DREG-
56), CD80 (L307.4), CD83 HB15e), CD86 (FUN-1), CD95
(DX 2), CD95L (G247–4),CD122 (MiK-
 
 
 
2), CD152 (BNI3.1),
CD154 (TRAP 1), HLA-DR (G46–6), and respective mouse and
rat isotype controls were employed. Abs used for intracellular cy-
tokine staining were FITC- and PE-conjugated anti–IL-2
(MQ1–17H12), anti–IL-4 (8D4–8), anti–IL-10 (JES3–19F1), and
anti–IFN-
 
 
 
 (4S.B3; all from BD PharMingen). Unconjugated
anti–IL-10 (JES3–19F1) (BD PharMingen) was used for neu-
tralization experiments, anti-CD3 (UCHT1) and anti-CD28
(CD28.2) for polyclonal activation of T cells.
 
Cytokine Assays.
 
T cells were stimulated with allogeneic DCs
or with platebound anti-CD3 (10 
 
 
 
g/ml) plus soluble anti-CD28
(10 
 
 
 
g/ml) in X-VIVO-20 plus 1% serum. Cytokine analysis was
performed at different time points by analysis of supernatants with
commercially available ELISA kits for human IL-10, IFN-
 
 
 
 (Bio-
source International), and TGF-
 
 
 
 (BD PharMingen). IL-2, IL-4,
IL-5, IFN-
 
 
 
, and TNF-
 
 
 
 were measured by a cytometric bead ar-
ray (Th1/Th2 Cytokine CBA 1; BD PharMingen) according to
the manufacturer’s instructions. For analysis of intracellular cyto-
kine production T cells were either stimulated with 20 ng/ml
PMA and 500 
 
 
 
g/ml Ca
 
2
 
 
 
 ionophore A23187 (both from Sigma-
Aldrich) for 6 h or with platebound anti-CD3 and soluble anti-
CD28 Ab for 6 h. 2 
 
 
 
M monensin (Sigma-Aldrich) was added for
the last 5 h of culture. Cells were collected, washed, fixed, and sa-
ponine permeabilized (fix/perm solution; BD PharMingen) and
stained with cytokine specific Ab or isotype.
 
Cell Isolation and DC Generation.
 
DCs were generated from
buffy coats or leukapheresis products (both obtained from the
Dept. of Transfusion Medicine, University of Erlangen, Erlangen,
Germany, from healthy donors after informed consent was given)
as described previously (15, 16). In brief, PBMCs were isolated
by Ficoll density gradient centrifugation. Monocytes were iso-
lated by plastic adherence and cultured in RPMI 1640 medium,
supplemented with IL-4 and GM-CSF. At day 6 a maturation
cocktail (IL-1
 
 
 
, IL-6, PGE
 
2
 
, and TNF-
 
 
 
) was added. At day 7
nonadherent cells were harvested and constituted mature DCs
that were 
 
 
 
90% double positive for costimulatory molecules
(CD80, CD86) and CD83.
 
CD4
 
 
 
 T cells were isolated from PBMCs with a negative
CD4
 
 
 
 T cell isolation kit (Miltenyi Biotech). CD4
 
 
 
CD25
 
 
 
 T
cells were isolated from the pure, untouched CD4
 
 
 
 T cells using
CD25 microbeads (Miltenyi Biotech). Purity was assessed by
FACS
 
®
 
.
 
Flow Cytometric Analysis.
 
For immunofluorescence staining
cells were washed and stained for 20 min at 4
 
 
 
C with optimal di-
lution of each Ab. Cells were washed again and analyzed by flow
cytometry (FACScan™ and CELLQuest™ software; Becton
Dickinson). For analysis of intracellular CD152 cells were stained
for CD4 expression, fixed, and saponine permeabilized (fix/perm
solution; BD PharMingen) and stained with CD152-specific Ab
or isotype.
 
Fixation of CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD25
 
  
 
T Cells.
 
For fix-
ation experiments CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD25
 
  
 
T cells were
isolated and divided into three fractions. One part of each was ac-
tivated with platebound anti-CD3 and soluble anti-CD28 over-
night. Next day the stimulated parts and one resting part were
fixated with 2% paraformaldehyde for 1 h at 4
 
 
 
C. Thereafter, fix-
ated cells were washed extensively and used in regulation assays
together with the untreated fraction.
 
Induction of Anergized T Cells.
 
To induce anergized CD4
 
 
 
CD25
 
  
 
T cells with CD4
 
 
 
CD25
 
 
 
 T cells, both populations
were isolated as described. They were either used directly or
fixated as described above. 5 
 
 
 
 10
 
5
 
 of CD4
 
 
 
CD25
 
 
 
 and
CD4
 
 
 
CD25
 
  
 
T cells were cultivated either with platebound
anti-CD3 and soluble anti-CD28 (10 
 
 
 
g/ml each) or with allo-
geneic mature DCs (5 
 
 
 
 10
 
4
 
 cells) for 48 h in 48-well plates.
Thereafter, cells were harvested, washed, and used in prolifera-
tion experiments.
 
Proliferation Assays.
 
To assess proliferation of the differently
cultured CD4
 
 
 
 subtypes 10
 
5
 
 sorted T cells were incubated in
X-VIVO-20 with 5 
 
 
 
 10
 
3
 
 DCs in 96-well, U-bottomed plates
or 10 
 
 
 
g/ml of platebound anti-CD3 plus 10 
 
 
 
g/ml soluble
anti-CD28 in 96-well, flat-bottomed plates. For assessment of
regulatory properties 10
 
5
 
 resting CD4 CD25  autologous T cells
were cultured with 5   103 DCs or platebound anti-CD3 and
soluble anti-CD28 in 96-well, U-bottomed plates. Purified
CD4 CD25  and CD4 CD25  T cells, anergized CD4 CD25 
T cells or fixated CD4 CD25  and CD4 CD25  T cells were
added usually at a 1:1 ratio if not indicated differently. After
4–5 d of culture 3[H]Tdr (37 KBq/well) was added for addi-
tional 16 h. Proliferation was measured using a liquid scintilla-
tion counter.
Transwell Experiments. Transwell experiments were per-
formed in 24-well plates. 106 CD4 CD25  T cells were stimu-
lated with 5   104 DCs. In addition, 106 CD4 CD25 ,
CD4 CD25 , and anergized CD4 CD25  T cells were either
added directly to the culture or were placed in transwell chambers
(Millicell, 0.4  m; Millipore). After 5 d of coculture T cells were
transferred to 96-well plates (105 cells per well) in triplicates. Pro-
liferation was measured after 16-h pulse with 3[H]Tdr using a liq-
uid scintillation counter.
CFSE Labeling and Sorting. CD4 CD25  and CD4 CD25 
T cells were labeled with 0.5  M of CFSE (Molecular Probes)
for 15 min at 37 C. Reaction was stopped with ice-cold PBS
buffer and cells were washed extensively. 5   105 CD4 CD25 
CFSE-labeled T cells were then cultured with 5   105 unlabeled
CD4 CD25  T cells (and vice versa) with platebound anti-CD3
and soluble anti-CD28 in 48-well plates. Proliferation was con-
trolled by FACS® for different time points. After 48 h cells were
harvested and sorted on a FACSVantage™ (Becton Dickinson).
Sorted cells were used for further regulation assays.249 Dieckmann et al. Brief Definitive Report
Results
Coculture of CD4 CD25  and CD4 CD25  T Cells
Yields Low Proliferating, IL-10–producing T Cells. CD4 
CD25  and CD4 CD25  subpopulations were separated
by MACS® from healthy donors. Separately or mixed at a
1:1 ratio the cells were stimulated polyclonally with plate-
bound anti-CD3 and soluble anti-CD28 or with mature al-
logeneic DCs. As shown before coculture of CD4 CD25 
and CD4 CD25  T cells results in a constantly low-prolif-
erating T cell population (unpublished data). We analyzed
the supernatant of this coculture after various time points
for different cytokines and found a high level of IL-10 pro-
duction peaking 48 h after onset of culture (Fig. 1 A). As
shown before CD4 CD25  T cells alone also produce size-
able amounts of IL-10 ( 200 pg/ml). One might speculate
that IL-10 production was only attributable to CD4 
CD25  T cells, but IL-10 production in the coculture was
2–4 times higher than production of CD4 CD25  T cells
alone (Fig. 2, A and B). Intracellular FACS® revealed that
the number of IL-10–producing cells more than doubled
(Fig. 1 C). High IL-10 production after 48 h of coculture
was observed regardless if polyclonal activation (platebound
anti-CD3 and soluble anti-CD28) or allogeneic mature
DCs were used (Fig. 1 B). In none of the cultures increased
production of TGF-  or Inf-  could be observed (unpub-
lished data). CD4 CD25  T cells alone did not produce
significant amounts of IL-10 (Fig. 1, A–C).
Activated, Paraformaledhyde-fixed CD4 CD25  T Cells
Show Similar Regulatory Capacity as Viable Cells. It is
known that CD4 CD25  T cells exert their regulatory
function in a cell contact–dependent yet cytokine-inde-
pendent manner. To further analyze their regulatory func-
tion, isolated CD4 CD25  T cells were divided into three
parts. One was activated overnight polyclonally with plate-
bound anti-CD3 and soluble anti-CD28 and fixed thereaf-
ter with paraformaldehyde (“activated-fixed”), the second
part was fixed with paraformaldehyde without prior activa-
tion (“resting-fixed”), and the third part was left untreated
(“viable”). After this procedure the three differently treated
fractions of CD4 CD25  T cells were used in regulation
assays with syngenic CD4 CD25  T cells. As shown in
Fig. 2 A activated-fixed CD4 CD25  T cells had a similar
regulatory capacity as their normal viable counterpart. This
is in sharp contrast to resting-fixed CD4 CD25  T cells
that do not show any regulatory function at all. Activated-
fixed and viable CD4 CD25  T cells almost completely
suppressed proliferation of CD4 CD25  T cells when a 1:1
ratio was used. This underlines and extends prior findings
on the regulatory function, demonstrating that surface mol-
ecules induced after activation of CD4 CD25  are respon-
sible for the regulatory capacity of these cells.
CD4 CD25  Regulatory T Cells Induce IL-10 Production
in Anergized CD4 CD25  T Cells in a Cell Contact–depen-
dent Manner. In further experiments we used the above
mentioned findings to analyze the requirements for induc-
tion of IL-10–producing anergized CD4 CD25  T cells.
CD4 CD25  and CD4 CD25  T cells were either
cultured alone or at a 1:1 ratio with normal viable
CD4 CD25  T cells, activated-fixed CD4 CD25  T cells,
resting-fixed CD4 CD25  T cells, or in a transwell setting.
IL-10 production was measured 48 h after onset of culture.
As shown in Fig. 2 B a high level IL-10 production was
achieved in coculture either with viable CD4 CD25  or
activated-fixed CD4 CD25  T cells. In transwell experi-
ments IL-10 production similar to CD4 CD25  T cells
alone was observed and CD4 CD25  T cells alone pro-
duced negligible amounts of IL-10.
CD4 CD25  T Cells Anergized by CD4 CD25  T Cells
Suppress Activation of Syngenic CD4  T Cells in an IL-10–
dependent Manner. IL-10 is known as a cytokine with potent
immunosuppressive function. Therefore, it was tempting
Figure 1. Coculture of CD4 CD25  and CD4 CD25  T cells results
in high level IL-10 production. CD4 CD25  and CD4 CD25  T cells
were MACS® sorted from PBMCs of healthy individuals. These cells were
either cultured alone or at a 1:1 ratio and activated with platebound anti-
CD3 and soluble anti-CD28 (10  g/ml, respectively). (A) After various
time points supernatants were analyzed for cytokine production by ELISA.
IL-10 production peaked 48 h after onset of culture and was markedly
higher in the coculture of CD4 CD25  and CD4 CD25  T cells than in
the cultures of each of the cell types alone. A representative out of five in-
dependent standardized experiments is shown. No elevated levels of INF- 
or TGF-  could be measured (data not shown). (B) The different T cell
populations were also activated with mature allogeneic DCs (DC/T cell
ratio 1:20) compared with anti-CD3 and anti-CD28 (10  g/ml, respec-
tively). Cytokines were measured 48 h after onset of culture. Results were
similar in five independent experiments. (C) For the last 6 h of activation
with anti-CD3 and anti-CD28 2  M monensin was added to the cultures.
Staining of CD4 surface expression was performed. Cells were washed,
fixed, permeabilized, and stained for intracellular IL-10 using PE-conju-
gated specific Abs. One of five independent experiments is shown.250 Induction of Type 1 Regulatory T Cells by CD4 CD25  T Cells
to speculate that the high IL-10 production of anergized
CD4 CD25  T cells would lead to secondary suppression
of other T cells. In the next set of experiments we sought
to investigate this matter. As it is known that IL-10 can act
indirectly on T cells via influence on APC, we choose a
polyclonal, cell-free T cell stimulus (platebound anti-CD3
and soluble anti-CD28) and mature allogeneic DCs, be-
cause they are known as the most powerful APC and
largely resistant to IL-10 (17). CD4 CD25  and CD4 
CD25  T cells alone or at a 1:1 ratio were stimulated
with allogeneic DCs (Fig.3, top panel) or with bound anti-
CD3 and soluble anti-CD28 (Fig. 3, bottom panel) for
48 h. Thereafter, cells were either fixed with paraformal-
dehyde or used viable. As expected activated CD4 CD25 
T cells induced strong suppression of CD4  prolifera-
tion and at a 1:1 ratio almost abolished it, whereas activated
CD4 CD25  T cells did not alter proliferation of syngenic
CD4  T cells. When the cocultured CD4 CD25  and
CD4 CD25  T cells were used in regulation assays, they
mediated a strong inhibition of CD4  T cell proliferation
(Fig. 3). This phenomenon was seen regardless of the stim-
ulus used (Fig. 3, top and bottom panel). We further added
anti–IL-10 Ab to the regulation assay or performed it in a
transwell setting. As shown before, anti–IL-10 did not alter
suppressive function of pure CD4 CD25  T cells, whereas
in a transwell setting CD4 CD25  T cells could not medi-
ate suppression. The opposite was true for regulation by
anergized CD4 CD25  T cells. Addition of IL-10 Abs al-
most completely abolished inhibition, whereas a transwell
setting did not markedly change the regulatory function of
these cells, suggesting that inhibition is mediated domi-
nantly by secretion of IL-10 (Fig. 3). Similar effects were
seen with polyclonally or allogeneic stimulated cells (Fig. 3,
top and bottom panel).
To further exclude that the observed effects are mediated
by CD4 CD25  T cell directly we performed CFSE la-
beling and FACS® sorting experiments. CD4 CD25  T
cells were labeled with CFSE and then mixed with
CD4 CD25  unlabeled T cells at a 1:1 ratio. This mixture
was stimulated with immobilized anti-CD3/soluble anti-
CD28 for 48 h. Thereafter, cells were sorted by FACS®
Figure 2. Activated fixed CD4 CD25  T cells show similar regulatory
potential as viable CD4 CD25  T cells and can induce IL-10 production
in CD4 CD25  T cells. (A) CD4  T cell subpopulations were sorted by
MACS® CD4 CD25  T cells were divided into three fractions. One part
was activated with platebound anti-CD3 (10  g/ml) and soluble anti-
CD28 (10  g/ml) overnight and fixed the next day with paraformalde-
hyde 2% (activated-fixed). The third part was fixed with paraformalde-
hyde without activation (resting-fixed) and the second part was left
untreated (viable). Each fraction was mixed with syngeneic CD4 CD25 
T cells at a 1:1 ratio (105 T cells per 96 well) and stimulated with plate-
bound anti-CD3 (10  g/ml) and soluble-anti-CD28 (10  g/ml). Prolif-
eration was determined by 3[H]Tdr incorporation after 5 d. Results are
representative of five independent experiments, shown as mean cpm of
triplicate cultures. Similar results were observed when T cells were stimu-
lated with mature allogeneic DCs (DC/T cell ratio of 1:20; data not
shown) (B) CD4 CD25  and CD4 CD25  T cells were either cultured
alone or CD4 CD25  T cells were mixed at a 1:1 ratio with activated-
fixed, resting-fixed or viable CD4 CD25  T cells. T cells were stimu-
lated with mature allogeneic DCs at the same ratio as in A. In a parallel
transwell approach CD4 CD25  T cells were stimulated with allogeneic
DCs (DC/T ratio 1:20) in a transwell chamber, and CD4 CD25  T cells
were placed in the well together with allogeneic DCs again at a DC/T
ratio of 1:20. IL-10 production was measured by ELISA 48 h after onset
of culture. Results were similar in five independent experiments.
Figure 3. CD4 CD25  T cells anergized by CD4 CD25  T cells sup-
press proliferation of CD4  T cells in a IL-10–dependent manner.
MACS® sorted CD4 CD25  and CD4 CD25  T cells were either cul-
tured alone or mixed at a 1:1 ratio (2   106 T cells per 24 well) and stim-
ulated with mature allogeneic DCs (DC/T cell ratio 1:20) or immobi-
lized anti-CD3/soluble anti-CD28. After 48 h of culture cells were
harvested and one fraction of each population was fixed with paraformal-
dehyde for 1 h. Viable and fixed cells were cocultured with syngeneic
resting CD4 CD25  T cells at a 1:1 ratio (105 T cells per 96 well) and
stimulated as before with immobilized anti-CD3/soluble anti-CD28
(bottom panel) or mature allogeneic DCs (top panel) in the presence or
absence of 10  g/ml anti–IL-10 Abs. In a parallel transwell approach the
three different T cell populations were placed in a transwell chamber and
resting CD4 CD25  T cells were stimulated with DCs (DC/T cell ratio
1:20; top panel) or platebound anti-CD3/soluble anti-CD28 (bottom
panel) in the well. Proliferation after 5 d was determined by 3[HT]Tdr in-
corporation. One out of four independent experiments is shown.251 Dieckmann et al. Brief Definitive Report
and used in regulation assays with syngenic CD4 CD25  T
cells. As shown in Fig. 4 regulation was mediated by both
the labeled and unlabeled fractions, which was abolished by
addition of anti–IL-10 in the case of unlabeled (anergized
CD4 CD25  T cells). Not surprisingly activated CD4 
CD25  T cells showed inhibition of T cells proliferation
themselves. This could not be abolished by anti–IL-10,
clearly demonstrating that anergized CD4 CD25  T cells
mediate suppression via IL-10 which is distinct from the
mechanisms used by CD4 CD25  T cells.
Anergized CD4 CD25  T Cells Predominantly Produce
IL-10. To analyze the cytokine secretion pattern of an-
ergized CD4 CD25  T cells, CD4 CD25  and CD4 
CD25  T cells were sorted and stimulated alone or at a 1:1
mixture as described before. After 48 h of culture superna-
tants were analyzed for the cytokines IL-2, IL-4, IL-5,
TNF- , and INF-  by a cytometric bead array, which al-
lows multiparameter analysis in a single sample. As shown
in Fig. 4 anergized CD4 CD25   T cells similar to
CD4 CD25  T cells do only produce very low levels
of TNF-  and INF-  and no IL-2, IL-4, or IL-5.
CD4 CD25  T cells on the other hand produce high lev-
els of IL-2, TNF- , and INF-  and low to moderate levels
of IL-4 and IL-5, resembling a Th1 phenotype.
Surface phenotyping with the Abs mentioned in material
and method did not reveal striking differences between ac-
tivated CD4 CD25 , activated CD4 CD25 , and cocul-
tured CD4 CD25 /CD4 CD25  T cells after 48 h of ac-
tivation (unpublished data).
Discussion
The important in vivo function of CD4 CD25  regula-
tory T cells has been thoroughly demonstrated in rodents
(1–3). Lately, we and others have shown that a similar pop-
ulation of regulatory T cells also exists in humans. These
findings have been confirmed and extended by several
groups up to now (4–8, 18–22). Still numerous characteris-
tics of CD4 CD25  T cells need to be explained. One
important question that has to be answered is how
CD4 CD25  T cells execute their important function in
vivo, as they only constitute a small population of periph-
eral CD4  T cells (average 6%), that need direct cell con-
tact as well as stimulation via the TCR to suppress un-
wanted T cell activation. In vitro studies usually employ
high ratios of CD4 CD25 /CD4 CD25  T cells, a situa-
tion that is hard to imagine at an inflammatory site in vivo.
As described, coculture of CD4 CD25  and CD4 
CD25  T cell leads to marked reduction of T cell prolifer-
ation (6). This effect is stable for several days (unpublished
data). Although CD4 CD25  T cells produce sizeable
quantities of IL-10 this cytokine does not seem to be re-
sponsible for the regulatory effects (6). We analyzed the
supernatant of CD4 CD25  and CD4 CD25  cocultures
and found that high levels of IL-10 are produced, peaking
after 48 h. IL-10 levels in the coculture were markedly
higher than IL-10 produced by CD4 CD25  T cells
alone, suggesting that it was not only attributable to
CD4 CD25  T cells. This was further confirmed by in-
tracellular FACS® analysis. IL-10 is known to inhibit cy-
tokine production from T cells (23) and exert antiinflam-
matory and suppressive effects on most haematopoietic
cells. It is also involved in the induction of peripheral tol-
erance via effects on T cell–mediated responses (23). IL-10
indirectly suppresses T cell responses by potently inhibit-
ing the antigen-presenting capacity of APC, including
DCs (24), Langerhans cells, and macrophages (25). In ad-
dition, IL-10 directly regulates T cells by inhibiting their
Figure 4. (A) Anergized CD4 CD25  T cells predomi-
nantly secrete IL-10. CD4 CD25  and CD4 CD25  T
cells were isolated as described and stimulated alone or at a
1:1 ratio with anti-CD3/anti-CD28. 48 h after stimulation
supernatant was harvested and analyzed by a cytometric
bead array for IL-2, IL-4, IL-5, TNF- , and INF- . Re-
sults were similar in five independent experiments. (B) Be-
fore mixing CD4 CD25  and CD4 CD25  T cells at a
1:1 ratio, CD4 CD25  T cells were labeled with 0.5  M
CFSE for 15 min. Cells were then mixed and stimulated
with immobilized anti-CD3/soluble anti-CD28. After 48 h
cells were harvested and sorted on a FACSVantage™. The
positive and the negative fraction were then cocultured
with syngeneic resting CD4 CD25  T cells (105 T cells
per 96 well). Proliferation was measured after 5 d by
3[HT]Tdr incorporation. One out of five independent ex-
periments is shown.252 Induction of Type 1 Regulatory T Cells by CD4 CD25  T Cells
ability to produce IL-2, TNF-  (26), IL-5 (27), and to
proliferate (28).
It was important to rule out the effects seen were not
only due to CD4 CD25  T cells in the coculture. In a set
of pilot experiments we could show that CD4 CD25  T
cells when paraformaldehyde-fixed after polyclonal ac-
tivation have similar regulatory properties as viable
CD4 CD25  T cells. In coculture experiments, using acti-
vated-fixed and viable CD4 CD25  T cells together with
CD4 CD25  T cells, it turned out that IL-10 production
remained high, even if activated-fixed CD4 CD25  T
cells were used. This showed that IL-10 production was
not attributable to increased production by CD4 CD25 
but due to the anergized CD4 CD25  T cells. In a parallel
transwell approach we showed that direct cell contact be-
tween CD4 CD25  and CD4 CD25  T cells is necessary
to prime CD4 CD25  T cells to become IL-10 producers.
Further experiments were performed to analyze which
effect this high level of IL-10 might have on T cell prolifer-
ation. Indeed it was shown that proliferation of syngenic
CD4  T cells could be markedly decreased by anergized
CD4 CD25  T cells. Addition of anti–IL-10 abolished the
suppressive effects of anergized CD4 CD25  T cells, while
a transwell setting permitting the free exchange of soluble
factors, but no cell contact, did not change suppression.
Furthermore, we CSFE-labeled CD4 CD25  T cells and
separated them from CD4 CD25  T cells after 48 h of
coculture by FACS® sorting. Both populations strongly in-
hibited CD4  T cell proliferation which was almost abol-
ished in the unlabeled e.g., CD4 CD25  fraction by the
addition of anti–IL-10, demonstrating that IL-10 indeed
is crucial for the suppressive function of anergized
CD4 CD25  T cells. This is not surprising, as other re-
ports have shown that activation of human CD4  T cells in
the presence of IL-10 results in a state of functional unre-
sponsiveness without death, termed anergy (19). CD4  T
cells with low proliferative capacity that are generated in
the presence of IL-10 have been termed Tr1. The cells that
are generated in the presence of CD4 CD25  T cells show
some characteristics resembling Tr1 cells, especially their
low proliferative capacity and the high level production of
IL-10. But in some instances they differ, as Tr1 are also de-
fined by their ability to produce TGF-  and anergized
CD4 CD25  T cells did not produce significant amounts
of TGF-  at least by the assay used. Further on we clearly
demonstrate that cell contact between CD4 CD25  and
CD4 CD25  T cells and not IL-10 is crucial for the induc-
tion phase of inhibitory, anergized, IL-10–producing,
CD4 CD25   T cells. But as coculture of anergized
CD4 CD25  with syngenic resting CD4 CD25  T cells
results in anergic, IL-10–releasing CD4 CD25  T cells this
IL-10 production may then also contribute to the genera-
tion of Tr1-like cells as described for Tr1 cells.
To distinguish between indirect effects via APC modula-
tion and direct effect on T cells we used as a stimulus not
only allogeneic DCs but also immobilized anti-CD3/solu-
ble anti-CD28 as a cell-free T cell stimulation system. As
the effects seen were independent of the stimuli used, a di-
rect effect on T cells is most likely.
The data presented here may serve as an explanation of
how CD4 CD25  T cells fulfill their important in vivo
function. At sites of inflammation if activated they would
anergize CD4  T cells in their close environment in an an-
tigen-unspecific bystander effect fashion (29). Our findings
suggest, however, that anergized CD4  T cells (including
pathogenic ones) in turn will produce high levels of IL-10,
thereby creating an immunosuppressive environment ei-
ther by indirect effect via influence on APC (30) or via di-
rect effects on other T cells thereby effectively abrogating
unwanted T cell activation.
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